Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma

Annals of Surgical Oncology

Volumn 14, Issue 10, 2007, Pages 2738-2747

  Kolev, Yanislav ^a   Uetake, Hiroyuki ^a   Iida, Satoru ^a   Ishikawa, Toshiaki ^a   Kawano, Tatsuyuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; COX 2; Gastric cancer; Prognosis; VEGF

Indexed keywords

CD34 ANTIGEN; CYCLOOXYGENASE 2; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; TISSUE SECTION; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICROCIRCULATION; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34648832065     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9484-7     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Lambert L, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and USA. Int J Cancer 2002;97:811-8
3. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-70
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
5. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16
6. Van Rees BP, Ristimäki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001;36:897-903
7. Saukkonen K, Nieminen O, Van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31
8. Han SL, Tang HJ, Hua YW, Ji SQ, Lin DX. Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg 2003;20:107-14
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6
10. Ribatti D., Vacca A., Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999;1:293-302
11. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002;96:1497-506
12. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-80
13. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104
14. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003;9:1421-6
15. Zheng S, Han MY, Xiao ZH, Peng JP, Dong Q. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003;9:1227-30
16. Morabito A, Sarmiento R, Bonginelli P, Gasparini G. Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol 2004;49:91-107
17. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL. Prognistic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004;14:815-23
18. Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001;92:2569-77
19. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58
20. Schlingemann RO, Rietveld FJR, de Waal RMW, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990;62:690-6
21. Hlatky L, Hahnfeltd P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93
22. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10-24
23. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-71
24. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 2000;82:339-47
25. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
26. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474-84
27. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000;89:1418-24
28. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63
29. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15:826-32
30. Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 2003;37:28-33
31. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 Expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002;66:222-9
32. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27
33. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-25
34. Schor AM, Pendleton N, Pazouki S, et al. Assesment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-56
35. Yoshida S, Amano H, Hayashi I, et al. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003;83:1385-94